share_log

Revance Therapeutics | 8-K: Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

SEC ·  Feb 28 13:15
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more